Short-term treatment duration for HCV-2 and HCV-3 infected patients

A. Andriulli, O. Dalgard, K. Bjøro, A. Mangia

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: We have shown that 12-14 weeks treatment is effective in HCV-2 or -3 patients with undetectable HCV-RNA after 4 weeks of therapy (rapid virologic response). Patients: To identify predictors of sustained virologic response, rapid virologic response and relapse following short treatment, we pooled data from the original Italian and Norwegian studies. Four hundreds and three patients were treated with PegIFN α-2b (1.0, n = 281 or 1.5 μg/kg, n = 122) and ribavirin (800-1200 mg) for 12-14 or 24 weeks, depending on negative or positive HCV-RNA at week 4. Results: Sustained virologic response differed between cases with and without rapid virologic response (85% versus 62%, P <0.0001), mild and severe fibrosis (83% versus 67%, P = 0.004), and HCV-2 and -3 (81% versus 73%, P = 0.05). In a regression model, RVR (odds ratio 3.49, confidence interval 1.73-5.36) and mild fibrosis (odds ratio 2.91, confidence interval 1.57-5.38) independently predicted sustained virologic response. Rapid virologic response was obtained in 274 (68%) patients, 163/242 (67%) HCV-2, and 111/161 (69%) HCV-3. Patients with RVR had more frequently mild fibrosis (70% versus 54%, P = 0.03), and high PegIFN dose (78% versus 64%, P = 0.005). In a regression model, mild fibrosis independently predicted rapid virologic response (odds ratio 1.87, confidence interval 1.10-3.16). In rapid virologic response patients, sustained virologic response was achieved in 85% of both HCV-2 and -3. Virologic relapse was observed in 10.6% rapid virologic response patients and was more frequent among those with low ALT (14% versus 2%, P = 0.04). Conclusion: In HCV-2 or -3, the HCV-RNA status after 4 weeks of therapy may guide treatment duration. HCV-2 and HCV-3 patients with severe fibrosis are less likely to experience both rapid virologic response and sustained virologic response, and more frequently relapse after a 12 or 14 weeks duration of antiviral therapy.

Original languageEnglish
Pages (from-to)741-748
Number of pages8
JournalDigestive and Liver Disease
Volume38
Issue number10
DOIs
Publication statusPublished - Oct 2006

Fingerprint

Fibrosis
Odds Ratio
RNA
Confidence Intervals
Therapeutics
Recurrence
Ribavirin
Antiviral Agents
Sustained Virologic Response

Keywords

  • Chronic hepatitis
  • HCV genotype
  • HCV infection
  • PegInterferon
  • Ribavirin
  • Therapy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Short-term treatment duration for HCV-2 and HCV-3 infected patients. / Andriulli, A.; Dalgard, O.; Bjøro, K.; Mangia, A.

In: Digestive and Liver Disease, Vol. 38, No. 10, 10.2006, p. 741-748.

Research output: Contribution to journalArticle

@article{a11c2e74c1654d5bbd08a71d8a920e4f,
title = "Short-term treatment duration for HCV-2 and HCV-3 infected patients",
abstract = "Background: We have shown that 12-14 weeks treatment is effective in HCV-2 or -3 patients with undetectable HCV-RNA after 4 weeks of therapy (rapid virologic response). Patients: To identify predictors of sustained virologic response, rapid virologic response and relapse following short treatment, we pooled data from the original Italian and Norwegian studies. Four hundreds and three patients were treated with PegIFN α-2b (1.0, n = 281 or 1.5 μg/kg, n = 122) and ribavirin (800-1200 mg) for 12-14 or 24 weeks, depending on negative or positive HCV-RNA at week 4. Results: Sustained virologic response differed between cases with and without rapid virologic response (85{\%} versus 62{\%}, P <0.0001), mild and severe fibrosis (83{\%} versus 67{\%}, P = 0.004), and HCV-2 and -3 (81{\%} versus 73{\%}, P = 0.05). In a regression model, RVR (odds ratio 3.49, confidence interval 1.73-5.36) and mild fibrosis (odds ratio 2.91, confidence interval 1.57-5.38) independently predicted sustained virologic response. Rapid virologic response was obtained in 274 (68{\%}) patients, 163/242 (67{\%}) HCV-2, and 111/161 (69{\%}) HCV-3. Patients with RVR had more frequently mild fibrosis (70{\%} versus 54{\%}, P = 0.03), and high PegIFN dose (78{\%} versus 64{\%}, P = 0.005). In a regression model, mild fibrosis independently predicted rapid virologic response (odds ratio 1.87, confidence interval 1.10-3.16). In rapid virologic response patients, sustained virologic response was achieved in 85{\%} of both HCV-2 and -3. Virologic relapse was observed in 10.6{\%} rapid virologic response patients and was more frequent among those with low ALT (14{\%} versus 2{\%}, P = 0.04). Conclusion: In HCV-2 or -3, the HCV-RNA status after 4 weeks of therapy may guide treatment duration. HCV-2 and HCV-3 patients with severe fibrosis are less likely to experience both rapid virologic response and sustained virologic response, and more frequently relapse after a 12 or 14 weeks duration of antiviral therapy.",
keywords = "Chronic hepatitis, HCV genotype, HCV infection, PegInterferon, Ribavirin, Therapy",
author = "A. Andriulli and O. Dalgard and K. Bj{\o}ro and A. Mangia",
year = "2006",
month = "10",
doi = "10.1016/j.dld.2006.06.006",
language = "English",
volume = "38",
pages = "741--748",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "10",

}

TY - JOUR

T1 - Short-term treatment duration for HCV-2 and HCV-3 infected patients

AU - Andriulli, A.

AU - Dalgard, O.

AU - Bjøro, K.

AU - Mangia, A.

PY - 2006/10

Y1 - 2006/10

N2 - Background: We have shown that 12-14 weeks treatment is effective in HCV-2 or -3 patients with undetectable HCV-RNA after 4 weeks of therapy (rapid virologic response). Patients: To identify predictors of sustained virologic response, rapid virologic response and relapse following short treatment, we pooled data from the original Italian and Norwegian studies. Four hundreds and three patients were treated with PegIFN α-2b (1.0, n = 281 or 1.5 μg/kg, n = 122) and ribavirin (800-1200 mg) for 12-14 or 24 weeks, depending on negative or positive HCV-RNA at week 4. Results: Sustained virologic response differed between cases with and without rapid virologic response (85% versus 62%, P <0.0001), mild and severe fibrosis (83% versus 67%, P = 0.004), and HCV-2 and -3 (81% versus 73%, P = 0.05). In a regression model, RVR (odds ratio 3.49, confidence interval 1.73-5.36) and mild fibrosis (odds ratio 2.91, confidence interval 1.57-5.38) independently predicted sustained virologic response. Rapid virologic response was obtained in 274 (68%) patients, 163/242 (67%) HCV-2, and 111/161 (69%) HCV-3. Patients with RVR had more frequently mild fibrosis (70% versus 54%, P = 0.03), and high PegIFN dose (78% versus 64%, P = 0.005). In a regression model, mild fibrosis independently predicted rapid virologic response (odds ratio 1.87, confidence interval 1.10-3.16). In rapid virologic response patients, sustained virologic response was achieved in 85% of both HCV-2 and -3. Virologic relapse was observed in 10.6% rapid virologic response patients and was more frequent among those with low ALT (14% versus 2%, P = 0.04). Conclusion: In HCV-2 or -3, the HCV-RNA status after 4 weeks of therapy may guide treatment duration. HCV-2 and HCV-3 patients with severe fibrosis are less likely to experience both rapid virologic response and sustained virologic response, and more frequently relapse after a 12 or 14 weeks duration of antiviral therapy.

AB - Background: We have shown that 12-14 weeks treatment is effective in HCV-2 or -3 patients with undetectable HCV-RNA after 4 weeks of therapy (rapid virologic response). Patients: To identify predictors of sustained virologic response, rapid virologic response and relapse following short treatment, we pooled data from the original Italian and Norwegian studies. Four hundreds and three patients were treated with PegIFN α-2b (1.0, n = 281 or 1.5 μg/kg, n = 122) and ribavirin (800-1200 mg) for 12-14 or 24 weeks, depending on negative or positive HCV-RNA at week 4. Results: Sustained virologic response differed between cases with and without rapid virologic response (85% versus 62%, P <0.0001), mild and severe fibrosis (83% versus 67%, P = 0.004), and HCV-2 and -3 (81% versus 73%, P = 0.05). In a regression model, RVR (odds ratio 3.49, confidence interval 1.73-5.36) and mild fibrosis (odds ratio 2.91, confidence interval 1.57-5.38) independently predicted sustained virologic response. Rapid virologic response was obtained in 274 (68%) patients, 163/242 (67%) HCV-2, and 111/161 (69%) HCV-3. Patients with RVR had more frequently mild fibrosis (70% versus 54%, P = 0.03), and high PegIFN dose (78% versus 64%, P = 0.005). In a regression model, mild fibrosis independently predicted rapid virologic response (odds ratio 1.87, confidence interval 1.10-3.16). In rapid virologic response patients, sustained virologic response was achieved in 85% of both HCV-2 and -3. Virologic relapse was observed in 10.6% rapid virologic response patients and was more frequent among those with low ALT (14% versus 2%, P = 0.04). Conclusion: In HCV-2 or -3, the HCV-RNA status after 4 weeks of therapy may guide treatment duration. HCV-2 and HCV-3 patients with severe fibrosis are less likely to experience both rapid virologic response and sustained virologic response, and more frequently relapse after a 12 or 14 weeks duration of antiviral therapy.

KW - Chronic hepatitis

KW - HCV genotype

KW - HCV infection

KW - PegInterferon

KW - Ribavirin

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=33748494889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748494889&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2006.06.006

DO - 10.1016/j.dld.2006.06.006

M3 - Article

C2 - 16916631

AN - SCOPUS:33748494889

VL - 38

SP - 741

EP - 748

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 10

ER -